ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 646

Do Ethnicity, Degree of Family Relationship, and the Spondyloarthritis Subtype in Affected Relatives Influence the Association between a Positive Family History for Spondyloarthritis and HLA-B27 Carriership? Results from the Worldwide ASAS Cohort

Miranda van Lunteren1, Alexandre Sepriano1,2, Robert B.M. Landewé3,4, Joachim Sieper5,6, Martin Rudwaleit6,7, Désirée van der Heijde1 and Floris van Gaalen1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal, 3Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, 4Rheumatology, Zuyderland Hospital, Heerlen, Netherlands, 5German Rheumatism Research Centre, Berlin, Germany, 6Rheumatology, Charité Campus Benjamin Franklin, Berlin, Germany, 7Internal Medicine and Rheumatology, Klinikum Bielefeld Rosenhöhe, Bielefeld, Germany

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: axial spondyloarthritis, human leukocyte antigens (HLA) and race/ethnicity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) defines a positive family history (PFH) of spondyloarthritis (SpA) as presence of ankylosing spondylitis (AS), acute anterior uveitis (AAU), reactive arthritis (ReA), inflammatory bowel disease (IBD), and/or psoriasis in first (FDR)- or second (SDR)-degree relatives. In two European cohorts (SPACE and DESIR) a PFH of AS and AAU, but not other subtypes, were associated with HLA-B27 carriership in patients suspected of axial SpA (axSpA)1. As the importance of ethnicity or degree of family relationship is unknown, we investigated the influence of ethnicity, FDR or SDR on the association between a PFH and HLA-B27 carriership in patients suspected of axSpA.

Methods: Univariable analyses were performed among patients suspected of axSpA in the ASAS cohort at baseline. Each disease (AS, AAU, psoriasis, IBD, ReA) in a PFH according to the ASAS definition was a determinant in separate models with HLA-B27 carriership as outcome. Analyses were stratified for self-reported ethnicity (white, Asian, and other), FDR, and SDR. Analyses were repeated in multivariable models to investigate independent associations.

 

Results: In total, 594 patients were analysed. Patients had a mean (SD) age of 33.7 (11.7) years, 46% were male; 52% was HLA-B27+, 59% were white, 36% were Asian, and 5% had another ethnicity. A PFH was reported by 23% of the patients; a PFH of AS was the most (15%) and PFH of AAU (1%) the least often reported family history among all patients. A PFH in first-degree relatives was reported in 19% of patients and in second-degree relatives in 4%. A PFH was associated with HLA-B27 carriership in patients with a white (OR:2.3, 95%CI:1.4-3.9) or Asian ethnicity (OR:3.1, 95%CI:1.6-5.8) and with a PFH in FDR (OR:2.9, 95%CI:1.8-4.5) , but not with a PFH in SDR (OR:1.7, 95%CI:0.7-3.8) or in other ethnicities (Table 1). A PFH of AS was positively associated with HLA-B27 carriership in all subgroups (white OR:7.1, 95%CI:2.9-17.1; Asian OR:5.7, 95%CI:2.5-13.2; FDR OR:7.8, 95%CI:3.8-16.0; SDR OR:3.7, 95%CI:1.2-11.6). A PFH of AAU, ReA, IBD, or psoriasis was never positively associated with HLA-B27 carriership. In the multivariate analysis, similar results were found.

Conclusion: In the international ASAS cohort, a PFH of AS, but not of AAU, ReA, IBD, or psoriasis, was associated with HLA-B27 carriership irrespective of ethnicity or degree of family relationship. These data, in combination with data from two European cohorts, show that a PFH of AS and possibly a PFH of AAU can be used to identify patients who are more likely to be HLA-B27 positive and therefore have an increased risk of axSpA.

References: 1 Ez-Zaitouni et al (2017), AR&T 2017;19(1):118.


Disclosure: M. van Lunteren, None; A. Sepriano, None; R. B. M. Landewé, None; J. Sieper, None; M. Rudwaleit, None; D. van der Heijde, None; F. van Gaalen, None.

To cite this abstract in AMA style:

van Lunteren M, Sepriano A, Landewé RBM, Sieper J, Rudwaleit M, van der Heijde D, van Gaalen F. Do Ethnicity, Degree of Family Relationship, and the Spondyloarthritis Subtype in Affected Relatives Influence the Association between a Positive Family History for Spondyloarthritis and HLA-B27 Carriership? Results from the Worldwide ASAS Cohort [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/do-ethnicity-degree-of-family-relationship-and-the-spondyloarthritis-subtype-in-affected-relatives-influence-the-association-between-a-positive-family-history-for-spondyloarthritis-and-hla-b27-carri/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/do-ethnicity-degree-of-family-relationship-and-the-spondyloarthritis-subtype-in-affected-relatives-influence-the-association-between-a-positive-family-history-for-spondyloarthritis-and-hla-b27-carri/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology